Overview

Autologous Adipose Derived Mesenchymal Stem Cells for Chronic Traumatic Brain Injury

Status:
Recruiting
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
The global objective of this study is to establish the safety and investigate the potential treatment effect of an intravenous infusion of HB-adMSCs (Hope Biosciences adipose-derived mesenchymal stem cells) on brain structure, neurocognitive/functional outcomes, and neuroinflammation after traumatic brain injury and/or hypoxic-ischemic encephalopathy in adults.
Phase:
Phase 2
Details
Lead Sponsor:
Hope Biosciences
Collaborator:
The University of Texas Health Science Center, Houston